Type 2 Diabetes Trial, Recruiting NCT07509671 Sponsor: AdventHealth Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT07509671
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been formally diagnosed with type 2 diabetes or pre-diabetes, confirmed by a blood sugar test result (HbA1c of 6.5 or higher for diabetes, or 5.7–6.4 for pre-diabetes)
  • You have had a nerve conduction test (a test that measures how well your nerves carry electrical signals) that shows signs of nerve damage in your legs or feet
  • You experience both pain and reduced feeling/sensation in your feet or legs due to nerve damage
  • Your pain is rated at least 4 out of 10 on a standard pain scale
  • You are 18 years of age or older
  • You are able to understand and agree to take part in the study by signing a consent form
  • You are able to attend follow-up appointments as required by the trial

Who may not be able to join:

  • Your nerve damage appears to be caused by something other than type 2 diabetes
  • You have type 1 diabetes (rather than type 2)
  • You have low levels of vitamin B12
  • You have low levels of folate (a type of B vitamin)
  • You have a thyroid condition that is not well controlled
  • You have other nutritional deficiencies that could affect your nerves (confirm with trial site)
  • You have an autoimmune condition (where the immune system attacks the body)
  • You have an inflammatory condition affecting the nerves (confirm with trial site)
  • You have HIV or AIDS
  • You have been exposed to heavy metals or toxins that could damage nerves
  • You have multiple myeloma (a type of blood cancer)
  • You have moderate to severe narrowing of the spine in the lower back that causes pain or weakness when walking

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 828-654-8546

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
AdventHealth
Registry
ClinicalTrials.gov
Start date
23 April 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Numerical Rating Scale (NRS); Average pain on Numerical Rating Scale (NRS); ≥50% improvement of pain; ≥75% improvement of pain

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov